🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In 2015 we treated this pt (refractory basal call ca, metastatic liver, bones, brain— in wheelchair) with nivolumab High TMB, PDL1 amp In CR 8.5+ years ⁦Aaron Goodman - “Papa Heme”⁩

Wafik S. El-Deiry, MD, PhD, FACP We would like to inform you that your post has been successfully published on Oncodaily. Thank you for sharing. oncodaily.com/blog/114671.ht…

My own experience with quinacrine - Wafik S. El-Deiry, MD, PhD, FACP Jeffrey Winkler Marmorstein Lab oncodaily.com/blog/114671.ht… #Cancer #CancerResearch #ClinicalTrial #OncoDaily #Oncology

A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation nature.com/articles/s4158…

A druggable cascade links methionine metabolism to epigenomic reprogramming in squamous cell carcinoma pnas.org/doi/10.1073/pn…

New law will aid R.I. cancer researchers, patients | Cumberland | valleybreeze.com valleybreeze.com/news/cumberlan…

Great presentations today at #eldeirylab meeting Legorreta Cancer Center at Brown University The Warren Alpert Medical School Brown University #LegorretaCancerCenter by visiting summer Morehouse School of Medicine medical student Brian Baker, and visiting high school students Harshita Ganga from Ohio and Tanush Talekar from Pennsylvania. Also

Elon Musk agrees: "good". Thank you, all of you 😘

Sometimes, cancer does not respond to anti-cancer therapies. To put it another way, anti-cancer therapies, sometimes, just do not stop the progression (growth) of cancer. However, the Nobel Prize-winning treatment with Immune Checkpoint Inhibitors (ICI), known as Immunotherapy,

#PaperSpotlight: On July 28, Mikhail V. Blagosklonny, MD PhD Professor Oncology from Roswell Park published a new #editorial in Aging, entitled, “Targeted cancer therapy: The initial high concentration may slow down the selection for resistance." #PressRelease: aging-us.com/news-room/targ… #lungcancer #cancer #research

Watch an #agingshort #video about this #editorial by @blagosklonny: "Targeted cancer therapy: The initial high concentration may slow down the selection for resistance." Roswell Park DOI: doi.org/10.18632/aging… #aging #lungcancer #cancer #brain #metastases #research #openaccess

Listen to an #audio recording of a #pressrelease about this #editorial: "Targeted cancer therapy: the initial high concentration may slow down the selection for resistance." soundcloud.com/aging-us/targe… #lungcancer #cancer #aging #soundcloud #podcast #openaccess #peerreviewed #press

From osimertinib to preemptive combinations Mikhail V. Blagosklonny, MD PhD Professor Oncology | Oncotarget Journal oncotarget.com/article/28569/…

ncbi.nlm.nih.gov/pmc/articles/P…